Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1787 - Frequency of L858R and L861Q EGFR Mutation in Triple Negative, Luminal and HER2 of Indonesian Breast Cancers Patients (548P)


18 Nov 2017


Poster lunch


Dini Budhiarko


Annals of Oncology (2017) 28 (suppl_10): x170-x172. 10.1093/annonc/mdx678


D. Budhiarko1, T.P. Putra1, A.T. Harsono2, N. Masykura1, D. Tjindarbumi3, G. Widjajahakim2, A. Utomo1

Author affiliations

  • 1 Cancer, Stem Cell and Cancer Institute, 13210 - Jakarta/ID
  • 2 Cancer Translational Research, Kalbe Genomics Laboratory, PT. Innolab Science Int'l, 13210 - Jakarta/ID
  • 3 Oncology, Dharma Nugraha Hospital, 13220 - Jakarta/ID


Abstract 1787


Epidermal growth factor receptor (EGFR) family members are known to have important roles in breast cancer development. Clinical trials of EGFR tyrosine kinase inhibitor (TKI) in unselected breast cancer patients have not yielded promising results. Moreover, the presence of TKI-sensitive EGFR mutations may be rare and has not been clarified in different breast cancer subtypes in Indonesia.


Direct DNA sequencing was used to determine specific EGFR mutations, namely L858R and L861Q informalin fixed paraffin embedded (FFPE) samples collected from 152 consecutive breast cancer patients treated in Dharmanugraha Hospital. The study was approved by Dharmanugraha ethics committee. The archived specimens comprised of luminal A (45%), triple-negative (27%), and HER2-positive subtypes (28%).


EGFR mutation, L858R and L861Q, was found in all subtypes of breast cancers. Overall prevalence of EGFR mutation L858R was 11.84% (18 of 152) and predominantly found in HER-2 positive subtype (13.95%), followed by TNBC subtype (12.20%) and luminal A subtype (10.29%). L861Q mutations were detected more frequently than L858R mutations (19.08% vs 11.84%, respectively). The L861Q mutation was found most frequently in luminal group (23.53%), followed by TNBC group (17.07%) and HER-2 positive group (13.95%).


Tyrosine kinase inhibitor-sensitive EGFR mutations were present in all types of breast cancers. The incidence of EGFR mutation of L861Q was higher than L858R. The mutation of L858R was distributed almost evenly in all type of breast cancers. On the other hand, L861Q was commonly found in luminal group compared with two other groups. Indonesian breast cancer patients harboring TKI-sensitive mutations may be eligible for clinical trials evaluating TKI efficacy.

Clinical trial identification

Legal entity responsible for the study

Institutional Review Board, Stem Cell and Cancer Institute


PT. Kalbe Farma


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.